ADMA Q3 2022 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+98.7% YoY

Gross Profit

$10M23.5% margin

Operating Income

-$9M-22.7% margin

Net Income

-$15M-36.3% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+21.2%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$301M

Total Liabilities

$200M

Stockholders' Equity

$100M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$21M	+98.7%
Gross Profit	$10M	$385,337	+2406.0%
Operating Income	-$9M	-$14M	+35.5%
Net Income	-$15M	-$18M	+15.9%

Revenue Segments

Product Revenue

$41M100%

License Revenue

$35,7080%

Geographic Segments

United States

$38M100%